Evidence map›Paper›PMID 25933160›Full record

ArticlePloS one2015

Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.

Ivy Wilkinson-Ryan, Julius Kim, Sojung Kim, Ferhat Ak, Lindzy Dodson, Marco Colonna, Matthew Powell, David Mutch, Dirk Spitzer, Ted Hansen and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.Journal of controlled release : official journal of the Controlled Release Society · 2019
    Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Ivy Wilkinson-RyanWashington University School of Medicine, Division of Gynecologic Oncology, St. Louis, United States of America.
Julius KimUniversity of Chicago, Department of Neuro-oncology, Chicago, United States of America.
Sojung KimWashington University School of Medicine, Department of Pathology and Immunology, St. Louis, United States of America.
Ferhat AkSaint Jans Gathuis Hospital, Department of SJG Apotheek, Weert, The Netherlands.
Lindzy DodsonSaint Louis University, Department of Biology, St. Louis, United States of America.
Marco ColonnaWashington University School of Medicine, Department of Pathology and Immunology, St. Louis, United States of America.
Matthew PowellWashington University School of Medicine, Division of Gynecologic Oncology, St. Louis, United States of America.
David MutchWashington University School of Medicine, Division of Gynecologic Oncology, St. Louis, United States of America.
Dirk SpitzerWashington University School of Medicine, Division of Surgery, St. Louis, United States of America.
Ted HansenWashington University School of Medicine, Department of Pathology and Immunology, St. Louis, United States of America.
Simon P GoedegebuureWashington University School of Medicine, Division of Surgery, St. Louis, United States of America.
David CurielWashington University School of Medicine, Division of Cancer Biology, St. Louis, United States of America.
William HawkinsWashington University School of Medicine, Division of Surgery, St. Louis, United States of America.
Washington University in St. Louis · USSaint Louis University · USUniversity of Chicago · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One strategy in cancer immunotherapy is to capitalize on the key immunoregulatory and antigen presenting capabilities of dendritic cells (DCs). This approach is dependent on efficient delivery of tumor specific antigens to DCs, which subsequently induce an anti-tumor T-cell mediated immune response. Human adenovirus serotype 5 (HAdV5) has been used in human studies for gene delivery, but has limited infection in DCs, which lack the proper receptors. Addition of the porcine fiber knob (PK) from porcine adenovirus type 4 to HAdV5 allows the virus to deliver genetic material via binding to glycosylated surface proteins and bypasses the coxsackie-and-adenovirus receptor required by wild-type HAdV5. In this study we explored the potential therapeutic applications of an adenovirus with PK-based tropism against cancers expressing mesothelin. Infectivity and gene transfer assays were used to compare Ad5-PK to wild-type HAdV5. Mouse models were used to demonstrate peptide specificity and T-cell responses. We show that the PK modification highly augmented infection of DCs, including the CD141+ DC subset, a key subset for activation of naïve CD8+ T-cells. We also show that Ad5-PK increases DC infectivity and tumor specific antigen expression. Finally, vaccination of mice with the Ad5-PK vector resulted in enhanced T-cell-mediated interferon gamma (IFN-γ) release in response to both mesothelin peptide and a tumor line expressing mesothelin. Ad5-PK is a promising tool for cancer immunotherapy as it improves infectivity, gene transfer, protein expression, and subsequent T-cell activation in DCs compared to wild-type HAdV5 viruses.

Indexed as

Genetic TherapyImmunotherapyAdenoviruses, HumanAdenoviruses, PorcineAnimalsCapsid ProteinsDendritic CellsGenetic VectorsGene Transfer TechniquesGPI-Linked ProteinsHumansMesothelinMiceNeoplasmsSwineTransduction, GeneticCapsid ProteinsGPI-Linked Proteinshexon capsid protein, AdenovirusMesothelinMsln protein, mouse

Identifiers

PMID25933160
PMCPMC4416912
OpenAlexW2334691713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.